Bone Morphogenetic Protein 4 (BMP4) for Treating Advanced Stage Neuroblastoma

Pediatric neuroblastoma in its advanced stage (st. IV) is usually lethal. 70% of the affected children die. 50% of the children show upon diagnosis metastasis or a genetic amplification of the oncogene N-myc. This group has a poor prognosis and a 5-year survival rate of only 33%. A drawback of the current standard therapy is the poor efficacy accompanied with severe side effects. Therefore a new treatment of neuroblastoma with a different antitumoral mode of action than the traditional cytotoxics is urgently required.

Further Information: PDF

DKFZ (German Cancer Research Center, Deutsches Krebsforschungszentrum)
Phone: +49-6221-42 2955

Contact
Dr. Ruth Herzog

Media Contact

info@technologieallianz.de TechnologieAllianz e.V.

Alle Nachrichten aus der Kategorie: Technology Offerings

Zurück zur Startseite

Kommentare (0)

Schreib Kommentar

Neueste Beiträge

Seasonal Forecasts Improve Food Supply

EU project CONFER started – precipitation forecasts reduce the impacts of droughts and floods in East Africa. Developing more precise seasonal forecasts to improve food supply for a total of…

Geologists simulate soil conditions to help grow plants on Mars

Humankind’s next giant step may be onto Mars. But before those missions can begin, scientists need to make scores of breakthrough advances, including learning how to grow crops on the…

Theoreticians show which quantum systems are suitable for quantum simulations

A joint research group led by Prof. Jens Eisert of Freie Universität Berlin and Helmholtz-Zentrum Berlin (HZB) has shown a way to simulate the quantum physical properties of complex solid…

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close